We are thrilled to announce that Children’s Cancer Hospital Egypt (CCHE) 57357 has been honored with the prestigious UAE International Genomics Award 2024 as a Health Innovation Trailblazer for its outstanding contributions to pediatric cancer research and personalized medicine. This recognition underscores our commitment to advancing healthcare through cutting-edge genomics and innovative patient care.
The Health Innovation Trailblazer Award is granted to academic individuals, academic institutes, and healthcare industry initiatives with impactful genetic research. CCHE 57357 won the 2024 regional award for the non-profit/ NGO sector.
CCHE received the 2024 Health Innovation Trailblazer Award for pursuing the best possible outcomes for children, commitment to evidence-based medicine, compassionate care, and unwavering dedication. Moreover, the award recognized CCHE for promoting innovation in genetic research that has the potential to drive significant improvement in the quality of life of patients, families, and healthcare providers. As the hospital is advancing solutions with a multifaceted research approach, the award was granted to CCHE on three interconnected fronts;
- Bridging Research and Clinical Practice:
As the largest pediatric oncology hospital worldwide, CCHE 57357 is committed to being a place of healing and a hub for cutting-edge research, which is one of the organization’s strategic goals.
At CCHE 57357, our commitment to advancing pediatric oncology extends beyond research—it’s about translating breakthroughs into tangible benefits for our young patients. CCHE labs exemplify the intersection of technology, precision, and patient-centric care.
Cutting-edge research meets clinical diagnostics in CCHE 57357 high-tech diagnostic clinical and surgical pathology CAP-accredited labs, where science fuels hope for a healthier future. Our dedication to excellence echoes through every diagnosis and every treatment plan. At CCHE 57357, research isn’t an abstract concept it’s a lifeline for our young warriors.
Clinical Pathology Lab: Unleashing Molecular Insights
The Clinical Pathology Lab at 57357 is a beacon of innovation equipped with cutting-edge technology. Within its walls, molecular and cytogenetic diagnostics take center stage. State-of-the-art equipment enables genetic analysis, including DNA sequencing and chromosomal studies. Moreover, the lab employs Next Generation Sequencing (NGS), a game-changer that swiftly decodes genetic information. The lab paves the way for targeted treatments guided by each patient’s unique genetic profile by identifying mutations and chromosomal abnormalities.
Surgical Pathology Lab: Where Automation Meets Precision
Meanwhile, the surgical pathology lab stands as a model of modernity, where automation meets precision. The entire workflow, from specimen processing to slide preparation, is fully automated, ensuring efficiency and accuracy. Additionally, the lab delves into the molecular intricacies of tumors through molecular and cytogenetic analysis. By understanding genetic markers, they refine diagnoses and tailor treatments, emphasizing
personalized care.
With a profound commitment to excellence and innovation, hand in hand with a keen sense of social responsibility and accountability, CCHE is utilizing these labs to serve and benefit the adult population from our surplus services production of the automated labs at a preferential cost. These unique lab services are offered to the adult population at a convenient price and the highest quality, contributing to the treatment journey of children with cancer.
- Genetic counseling clinic:
At CCHE 57357, we strongly emphasize personalized care for pediatric patients dealing with hereditary diseases. Our dedicated team of physicians and scientists operates the genetic counseling clinic, offering essential support and education to families navigating the complexities of these conditions. By doing so, we directly enhance patients’ lives and empower them to make informed decisions about their health.
Furthermore, CCHE 57357, in collaboration with Egypt Cancer Network 57357 (ECN USA), has made a strategic investment in the education of the genetic counseling clinic team. Earlier this year, the first accomplished graduate from Northwestern University in Chicago (one of the world’s leading genetic counseling programs) is back and oversees the genetic counseling clinic and a dedicated team of physicians and scientists. CCHE’s unwavering commitment to expanding this service locally and globally holds immense potential to impact countless families facing positively
these genetic challenges.
3. Basic Research Unit
In 2015, the hospital leadership decided to incorporate a fundamental research unit to delve into cancer-related questions, unraveling the intricate biology of the disease. Aiming to bridge the gap between theory and practice, the basic research unit initiative was the second foundation following the footsteps of the clinical research unit that was supported by an excellent digital data-driven approach with a focus on optimizing clinical data processes, monitoring protocols, conducting trials, and analyzing epidemiological data.
Focusing on genomic research, CCHE 57357 is running a Genomics and Epigenomics Research Program, an in-house laboratory boasting state-of-the-art equipment, including high-throughput technologies for genetic research and diagnostics. From whole genome sequencing to non-invasive prenatal testing (NIPT), our dedicated team works tirelessly to unravel genetic mysteries and improve patient outcomes.
CCHE 57357 launched several translational research initiatives and projects, exploring population genetic and epigenetic factors in acute myeloid leukemia, choroid plexus tumors, pineal pure germinomas, Duchenne Muscular Dystrophy, and spinal muscular atrophy. Our commitment to understanding the genetic basis of diseases drives progress.
The basic research unit runs seven specialized programs with researchers striving to uncover novel insights by working independently or collaborating on interdisciplinary projects. Active programs are imaging-based system biology, regenerative medicine, tumor biology, genomics and epigenomics, proteomics and metabolomics, microbiology and immunology, and clinical epidemiology.
Moreover, CCHE, launched in 2012, has a developed biorepository bank, a treasure trove of human biological specimens—tissues, blood, and body fluids—alongside meticulously annotated data awaiting future scientific exploration. This resource ensures that breakthroughs continue to emerge from the heart of CCHE 57357 and will enable researchers to delve deeper into the genetic factors of cancer, paving the way for discoveries and therapies.
CCHE 57357 is currently introducing the “Future Scientist Club”, which is an innovative program designed to inspire and nurture young minds with a passion for science and research. We aim to cultivate a new generation of researchers who will sustain our mission and contribute to the global scientific community. Through hands-on experiences and mentorship, we invest in the bright minds leading tomorrow’s scientific breakthroughs.
We sincerely thank H.E. Sheikh Nahyan Mabarak Al Nahyan, Dr. Maryam bin Matar, and the UAE Genetic Diseases Association for recognizing our efforts. Together, we continue to make significant strides in the fight against childhood cancer, paving the way for a healthier future.